News

F-652 was demonstrated to be safe in a Phase I study conducted in Australia in healthy volunteers in 2013. In addition, F-652 showed good pharmacokinetic (PK) and biomarker

The Cranbury facility is designed to utilize multiple technologies that enable rapid deployment of flexible manufacturing at commercial scale. Through the use of the latest single-use technologies, the

Burixafor (TG-0054) is a new, potent and selective chemokine receptor antagonist discovered by TaiGen. Around 15 patients will be enrolled in this open-label trial, which is designed to

The research is part of the Semiconductor Synthetic Biology (SSB) program sponsored and managed by Semiconductor Research Corporation (SRC), the world’s leading university-research consortium for semiconductor technologies. Launched

These new data support previously reported positive long-term safety and signs of visual improvement, as presented in The Lancet of October 15th, 2014. The Korean study published online

Lipocine previously announced positive top line efficacy from the SOAR clinical study in September 2014 and expects to announce top-line results from the 52 week safety assessment portion

I-STAR technology can rapidly screen antibodies from survivors of Ebola to uncover those with exceptional biologic activity that may lead to the development of a therapeutic antibody. BVGH,

This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors

The targeted enrollment has been achieved in both patient cohorts of the Phase 3 NOVA trial of niraparib, and TESARO expects data from NOVA in the fourth quarter